These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 14667132)

  • 1. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Hegedüs LM; Beck-Nielsen H; Abrahamsen B
    Calcif Tissue Int; 2003 Sep; 73(3):210-6. PubMed ID: 14667132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteoprotegerin and renal osteodystrophy.
    Coen G; Ballanti P; Balducci A; Calabria S; Fischer MS; Jankovic L; Manni M; Morosetti M; Moscaritolo E; Sardella D; Bonucci E
    Nephrol Dial Transplant; 2002 Feb; 17(2):233-8. PubMed ID: 11812872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
    Szymczak J; Bohdanowicz-Pawlak A
    Horm Metab Res; 2013 Sep; 45(10):759-64. PubMed ID: 23888411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metabolism in patients with primary hyperparathyroidism before and after surgery.
    Kerschan-Schindl K; Riss P; Krestan C; Rauner M; Bieglmayer C; Gleiss A; Fialka-Moser V; Niederle B; Pietschmann P
    Horm Metab Res; 2012 Jun; 44(6):476-81. PubMed ID: 22495973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased levels of osteoprotegerin in hemodialysis patients.
    Avbersek-Luznik I; Malesic I; Rus I; Marc J
    Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
    Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
    J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
    Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
    Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
    Franck H; Meurer T; Hofbauer LC
    J Rheumatol; 2004 Nov; 31(11):2236-41. PubMed ID: 15517638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of parathyroidectomy on lead mobilization from bone in patients with primary hyperparathyroidism.
    Osterode W; Winker R; Bieglmayer C; Vierhapper H
    Bone; 2004 Oct; 35(4):942-7. PubMed ID: 15454101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.
    Sasaki N; Kusano E; Ando Y; Nemoto J; Iimura O; Ito C; Takeda S; Yano K; Tsuda E; Asano Y
    Bone; 2002 Jun; 30(6):853-8. PubMed ID: 12052453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones.
    Grzegorzewska AE; Młot M
    Rocz Akad Med Bialymst; 2004; 49():193-6. PubMed ID: 15631342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
    Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
    Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
    Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
    Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients.
    Zheng CM; Chu P; Wu CC; Ma WY; Hung KC; Hsu YH; Lin YF; Diang LK; Lu KC
    Tohoku J Exp Med; 2012 Jan; 226(1):19-27. PubMed ID: 22156488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.